We certainly experienced interesting times in 2012. Before the year fades away in the anticipation of even more excitement to come (already we have William Baer at DOJ, Josh Wright at FTC, and Google settled), we once again present a dozen of our most read articles of 2012, chosen not only for their popularity but […]

This issue is a Santa grab bag with something for everyone—a collection of articles presenting the last word (for 2012 at least) on some of the issues we looked at this year. On the domestic front, Mandy Reeves analyzes how the Agencies’ reinvigorated litigation appetite affects merger analysis, Allen Grunes reveals the divergency between the […]

We’re looking at one of the most topical and controversial topics of 2012 – LIBOR. There’s a surprisingly strong antitrust connection. Restructuring proposals, as well as calculating potential criminal liabilities, will demand competition experience – requiring antitrust counsel and regulator expertise well into 2013 and more. In this issue, managed by Editorial Board Member Rosa […]

In Europe, the relations between National States and the EU receive constant attention, but in the United States relations between state and federal antitrust authorities only seem to get noticed when a state contradicts a federal action. But practitioners and corporate counsels—both national and international—would do well to pay vigilant attention. Our issue includes articles […]

So much of European competition news deals with the financial & political centers: London, Brussels, Paris, etc. Yet many of the most interesting challenges are faced by Central and Eastern European countries. In many cases, they’re dealing with a triple challenge – converting to a market economy, dealing with an economic downturn, and creating new […]

Antitrust is definitely heating up, even if the economy isn’t. This issue brings us current on a global scale by first looking at merger activity in the United States, England, and India. Then we bring our readers up-to-date with current authority activity, including the FTC vs. Google, criminalization in Australia, and further thoughts on the […]

One of the biggest challenges in antitrust is keeping technology issues straight. To help everyone stay informed, we asked some experts to bring us up to date. In particular, two of DG Comp’s tech authorities (Per Hellstrom & Thomas Kramler) discuss the issue they feel to be high on their list of concerns – patents. […]

Canada has the oldest antitrust authority in the world and they always seem to be pacesetters in competition policy. Our Canadian collection, organized by Mark Katz, highlights recent activities/controversies that are sure to spill over to the rest of the world. Our second collection includes three articles that follow-up on previous reports, including the question […]

During this month, we’ve been publishing papers from competition authorities describing ways to educate an audience that may not even understand what “competition policy” is. Part of the surprise has been the actual diversity of those audiences – not just the public, but fellow agencies, judges, and even other authorities. And as the Brazilians and […]

It’s far cheaper not to commit the crime then commit it and get caught. So it’s no surprise that the savvier competition authorities spend time and resources on outreach and advocacy. Given a myriad of audiences, however, it’s not easy. There are the obvious public and corporate constituencies, but fellow government agencies are just as […]

The final issue in our health series brings in a global perspective. Four of our authors take a look at the EU approach to pharm.; in particular, at the Italian Pfizer case, the Boehringer decision, and court developments since Astra-Zeneca: Is there a pattern? Back in the U.S. we wonder if K-Dur will force the Supreme Court […]

This second of our special health-care series concerns health care mergers, perhaps the thorniest antitrust issue that ObamaCare presents. While the ACA encourages cost savings through ACOs and other means, the antitrust authorities continue to be skeptical of health care institution mergers. Do all health care mergers fall between a rock and a hard place? Our […]